By Tapan Panchal

 

LONDON--GlaxoSmithKline PLC (GSK.LN) reported positive results Thursday for a new drug used in the treatment of asthma, a chronic lung disease that inflames and narrows the airways.

The pharmaceutical company said results from a non-inferiority lung function study showed that patients with well-controlled asthma were able to switch to the once-daily Relvar and Ellipta combination drug, from the twice-daily Seretide and Accuhaler combination drug without compromising their lung function.

GlaxoSmithKline is jointly developing the asthma drug with Innoviva Inc. (INVA).

Shares at 1011 GMT were unchanged at 1631 pence.

 

Write to Tapan Panchal at tapan.panchal@wsj.com

 

(END) Dow Jones Newswires

February 23, 2017 05:50 ET (10:50 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Innoviva Charts.
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Innoviva Charts.